A randomized, Double-blind, Placebo and Active controlled, Multicenter, Phase 3 Study to Access the Efficacy and Safety of Filgotinib Administered for 52 Weeks Alone and in Combination with Methotrexate (MTX) to Subjects with Moderately to Severely Active Rheumatoid Arthritis who Are Naive to MTX Therapy
Professor & Head, All India Institute of Medical Sciences (AIIMS), New Delhi
Accessibility Controls